| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
FORM 25 | ||
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. | ||
| Commission File Number 001-37452 | ||
| Issuer: | Celyad Oncology SA |
| Exchange: | Nasdaq Stock Market LLC |
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
| Address: | Rue Edouard Belin 12 Mont-Saint-Guibert, BELGIUM 1435 |
| Telephone number: | 32 10 39 41 05 |
| (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) |
| American Depositary Shares |
| (Description of class of securities) |
| Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration: |
| o 17 CFR 240.12d2-2(a)(1) |
| o 17 CFR 240.12d2-2(a)(2) |
| o 17 CFR 240.12d2-2(a)(3) |
| o 17 CFR 240.12d2-2(a)(4) |
| x Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1 |
| o Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange. |
| Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person. |
| 2023-07-10 | By | Aravind Menon | Hearings Advisor | |
| Date | Name | Title | ||
| 1 | Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions. |
Delisting Determination, The Nasdaq Stock Market, LLC, July 10, 2023,
Celyad Oncology SA
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the American Depositary Shares of Celyad Oncology SA
(the Company), effective at the opening of the trading session
on July 20, 2023.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5450(b)(1)(A).
The Company was notified of the Staff determination on May 10, 2023.
The Company did not appeal the Staff determination to the Hearings
Panel. The Company securities were suspended on May 19, 2023. The
Staff determination to delist the Company securities became final
on May 19, 2023.